- LDAA Submissions to the Senate Inquiry
- Counter-arguments and Responses
- Clinical Advisory Committee on Lyme Disease
- Patient surveys and statistical collection
LDAA Senate Inquiry Submission
LDAA Senate Inquiry Supplementary Submission
The Lyme Disease Association of Australia's supplementary submission (#528ss2) to the Senate Inquiry into Lyme-like illness in Australia.
Counter-arguments and Responses
The LDAA prepares and develops appropriate counter-arguments in response to other organizations position or policy statements which impact the Lyme Disease patient and related community members.
- LDAA's Counter-argument in response to the Royal College of Pathologists of Australasia position statement on Lyme Disease.
- LDAA's response to the Department of Health's statements on Lyme Disease issued 29 May 2015.
Clinical Advisory Committee on Lyme Disease
The LDAA performs a number of important functions relating to the Clinical Advisory Committee on Lyme Disease (CACLD) established and currently run by the Australian Government. The first is having secured a place for a patient representative on the committee to ensure patient requirements are sufficiently and adequately represented. The second is to respond to requests for public submissions from the CACLD by way of development and production of appropriate researched and informed responses.
The LDAA’s full submission:
Other Association and Group submissions:
Patient surveys and statistical collection
As many would be aware Lyme Disease in Australia is not currently notifiable so it is important the LDAA collects and collates necessary data to inform on-going strategy and development of necessary submissions and counter-arguments. If you are more visual head to our statistics section to see the reality of Lyme disease in Australia.
- 2013/14 Lyme Disease - Australian Patient Experience in 2013 (Coming soon - but check out our statistics section for an initial visual representation)
- 2011/12 Lyme Disease - Australian Patient Experience in 2012.